With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
PFE — frequently asked questions
Is Pfizer Inc. overvalued?
In our latest published analysis dated 2026-09-26, PFE screens modestly overvalued. The price recorded at analysis is USD 28.7 versus our fair value of USD 25.8; the high endpoint is presented separately as potential value of USD 28.9. That implies roughly 9.9% downside to fair value at that date.
Our latest published report, analyzed 2026-09-26, gives PFE a fair value of USD 25.8 and a potential value of USD 28.9. The conclusion is triangulated across multiple valuation models and weighted by reliability for Pfizer Inc.'s archetype; it is a dated research output, not a live price.
Should I buy PFE now?
Our latest published rating for PFE, analyzed 2026-09-26, is Reduce. Pfizer Inc. screens modestly overvalued at the analysis-date price of USD 28.7 versus fair value of USD 25.8; potential value is USD 28.9. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for PFE?
The dedicated bear-case section in our report analyzed 2026-09-26 documents Pfizer Inc.'s material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is PFE's rating?
Our latest published rating for PFE, analyzed 2026-09-26, is Reduce, with a published moat assessment of 6.5/10 (Narrow). It reflects our fair value of USD 25.8, the potential value of USD 28.9, and the price recorded at analysis (USD 28.7).
The biggest opportunity is faster-than-anticipated delivery of the 9.7 billion USD net cost reduction program through 2029 coupled with commercial acceleration in oncology assets like Padcev and positive Phase 2 clinical data from metabolic candidates addressing a 150 billion USD obesity market.
Main risk
Accelerated generic erosion on core blockbuster franchises Eliquis and Vyndaqel outpacing new commercial pipeline launches.
Pfizer is rated Reduce as its report-date price of 28.67 USD on September 25, 2026 stands 10.0% above our Fair value estimate of 25.83 USD, weighed down by upcoming patent cliffs and elevated balance-sheet leverage.3
Our house rating is Reduce. For an ordinary investor, this recommendation indicates trimming existing positions or deferring new capital commitments, as the current share price exceeds intrinsic value and presents an unfavorable risk-reward profile over the medium term.
As of September 25, 2026, Pfizer shares traded at 28.67 USD. Our valuation framework establishes a Fair value of 25.83 USD and a Potential value of 28.85 USD. The report-date price trades at a 10.0% premium to Fair value (representing negative 9.91% downside) and sits near Potential value, leaving essentially zero margin of safety for new capital.3
The primary risk to our view is an acceleration in generic patent cliff losses on key blockbuster medicines, notably Eliquis and Vyndaqel, outpacing new product commercialization. If generic competition intensifies rapidly, consolidated revenue would contract by more than 5.0% annually, while high total debt of 67.42 billion USD and 2.7x leverage would restrict capital allocation flexibility. Investors would see this deterioration through reported operating margins falling below 23.0% and deteriorating free cash flow conversion.1,3,4
The principal operational driver that can create value is management's 9.7 billion USD net cost realignment program through 2029, with 7.2 billion USD scheduled for completion by the end of 2026. Eliminating operational overhead and optimizing manufacturing can protect normalized operating margins at 26.0%, generating over 9.0 billion USD in annual free cash flow to service balance-sheet debt. If commercial execution in oncology and metabolic pipeline candidates exceeds expectations, share value could approach our Potential value of 28.85 USD.4,5
Substantial 9.7 Billion USD Net Cost Restructuring Program
Pfizer is delivering 7.2 billion USD in net cost savings by end-2026 and 9.7 billion USD cumulatively through 2029, defending operating margins and sustaining over 9.0 billion USD in annual free cash flow.5
Defensive Global Scale and Established Wholesaler Access
Wholesale distribution agreements with McKesson, Cencora, and Cardinal Health ensure broad pharmacy penetration across 51.66 billion USD in product sales, providing commercial cash flow stability.7
Pipeline Commercialization and Long-Term TAM Optionality
Oncology commercialization from Seagen and metabolic assets targeting a 150 billion USD obesity market offer post-2028 high single-digit growth optionality if Phase 2/3 trials succeed.4
House recommendation
We rate Pfizer a Reduce because the share price of 28.67 USD on September 25, 2026 exceeds our Fair value estimate of 25.83 USD by 10.0%, offering an unfavorable risk-reward balance during an extended loss-of-exclusivity transition.3
Under a severe operational stress test combining generic erosion across Eliquis and Vyndaqel with operational restructuring friction, operating margins would be capped at 21.0-22.0% rather than expanding to the 26.0% normalized target. Compounded by a 200 bps widening in cost of capital to reflect healthcare sector beta (0.9828) and elevated leverage on $67.42B of total debt, free cash flow conversion would decline significantly. If the exit multiple remains compressed at 11.0x, intrinsic value would drop to $17.56 to $22.53, forcing management to freeze dividend expansion and curtail discretionary investment.
Pfizer's competitive moat is evaluated as Narrow with a narrowing trend. The company's economic profit generation is anchored by a vast portfolio of patented biopharmaceuticals that produced $51.66B in product revenue and $1.65B in royalty revenue in FY2025. With FY2025 operating income of $15.44B, Pfizer achieved an ROIC of 11.92%, surpassing its moderate cost of equity (Ke) of 7.33% and WACC of 6.67%. However, because patent portfolios have finite lifespans, the impending loss of exclusivity on multi-billion-dollar blockbusters such as Eliquis and Vyndaqel over the medium term introduces cash flow cliffs that prevent the assignment of a Wide rating.
The highlighted cell is Fair value when every assumption sits at its base level ($25.83). Each row and column shows what Fair value becomes when one assumption moves.
Upgrade the rating; Re-examine margin expansion sustainability and reassess pipeline conversion milestones before adjusting portfolio exposure.
Trigger: Revenue and diluted earnings per share exceed the upper boundary of annual guided ranges, driven by accelerated commercial oncology adoption and faster delivery of operational cost reduction programs.
An upside operational surprise would demonstrate that cost realignment is running ahead of plan while new specialty launches successfully buffer generic erosion, improving intrinsic valuation toward $28.85.
In-line
Maintain Reduce; Verify quarterly restructuring milestones and balance sheet debt reduction progress before altering portfolio limits.
The global biopharmaceutical sector exhibits capital discipline, with industry capex-to-depreciation at 0.80 and industry capex-to-revenue at 1.1%. Pfizer reflects this contraction phase through capital expenditure moderation ($2.63B in FY2025 capex versus $6.59B in depreciation) and an aggressive $3.0B manufacturing optimization program designed to decommission redundant footprint.4,6
Bull cycle
The biopharmaceutical industry bull cycle is propelled by breakthrough clinical innovation in high-unmet-need categories such as targeted oncology and next-generation metabolic therapeutics. Aging demographic cohorts expand underlying chronic disease prevalence in developed economies, while rising middle-class healthcare access accelerates volume consumption in emerging markets. Commercialization of proprietary therapies commands premium pricing power, generating widening operating margins and multiples above 15.0x forward earnings.
§11 Position management
Sizing
1-2%
Given the Reduce rating, shares trade at $28.67, representing a premium over our synthesized Fair value midpoint of $25.83. With 2.7x leverage on $67.42B debt and upcoming patent expirations driving -3.97% FY2027 revenue contraction, investors should trim exposure to an underweight allocation of 1-2%.1,3,4
Risk
Risk management centers on monitoring balance sheet leverage and cash conversion during the patent cliff transition. With total debt of $67.42B and ongoing pressure on cash conversion and margin durability, debt service at 6.28% pre-tax cost of debt requires strict cash conservation. While $11.70B in annual supports the $1.72 annual dividend, equity exposure should remain restricted until leverage drops below 2.5x and generic erosion is demonstrably offset by pipeline launches.
§12 Investor perspectives
Institutional / Total Return Investor
Avoid
With the share price of 28.67 USD on September 25, 2026 sitting 10.0% above our Fair value of 25.83 USD, total return prospects are constrained by negative 9.91% intrinsic upside and revenue contraction of -3.97% projected in FY2027.1,3
Income / Dividend Investor
Hold
Existing income investors can hold shares for the 1.72 USD dividend, which remains supported by 9.08 billion USD in free cash flow, but should avoid adding new capital until total debt of 67.42 billion USD and 2.7x leverage are meaningfully reduced.
Growth Investor
Avoid
Top-line revenue faces patent cliff erosion over the medium term, while significant pipeline catalysts such as Phase 2 SOLIS-1 data will not read out until 2027, limiting growth momentum.
§14 Final recommendation
Action
Reduce
We recommend reducing exposure to Pfizer Inc. as the stock trades at 28.67 USD on September 25, 2026, representing a 10.0% premium over our Fair value estimate of 25.83 USD.3
While the 9.7 billion USD net cost reduction program defends profitability, upcoming loss of exclusivity on Eliquis and Vyndaqel and 67.42 billion USD in balance-sheet debt create persistent headwinds that skew the risk profile downward.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 chars
Sources
The records this analysis drew on, as they stood when it was run.
In the downside scenario, generic erosion on core blockbuster medicines outpaces pipeline contributions while operational restructuring faces execution friction that caps operating margins below targets. Elevated debt service costs combined with multiple compression restrict valuation recovery. Outside the dedicated bear-case section, downside risk is evaluated qualitatively as an operating boundary where revenue contraction deepens and leverage constraints preclude share repurchases. Disconfirmation would occur if quarterly margins deteriorate or key pipeline trials fail to achieve regulatory endpoints over the next eighteen months.
Ways this thesis can break
Accelerated generic erosion on core blockbuster franchises (Eliquis, Vyndaqel) outpaces pipeline commercialization, while restructuring friction caps operating margin below 22%, causing revenue and EPS to track the bear path and terminal multiple to de-rate to 11.0x.
Consensus estimates already project consolidated revenue contraction of -3.97% in FY2027 to $59.77B, and management acknowledges persistent loss-of-exclusivity headwinds keeping leverage elevated at 2.7x. Trigger occurs if consolidated revenue declines by more than 5% YoY over an 18-month horizon.1,4
FV impact
-6.3%
The analyst's bear scenario path and multiple as the base case
Trigger
Within 18 months
Credit re-pricing from elevated leverage and market beta convergence toward the healthcare sector baseline (0.98) elevates Pfizer's cost of capital by 200 bps, sharply reducing present value of long-dated cash flows.
Pfizer carries $67.42B in total debt against $1.14B in cash. Current moderate Ke of 7.33% is anchored to an adjusted beta of 0.536 despite sector beta of 0.9828. Trigger occurs if cost of equity rises above 9.33% within 12 months.2,3,6
FV impact
Market refuses to re-rate Pfizer from its current forward multiple of 9.67x toward the targeted 14.0x multiple due to prolonged pipeline trial timelines and persistent revenue contraction, compressing terminal multiple expectations by 20%.
Pfizer trades at 9.67x forward P/E, while the valuation framework models terminal multiple recovery toward 14.0x. If prolonged pipeline timelines and sustained revenue contraction cause the market to re-price terminal expectations down to 11.2x over 24 months, valuation impairs substantially.3
Early-warning signals to monitor
The five developments that would weaken our investment case.
Indicates restructuring friction in executing the $9.7B net cost reduction program, impairing margin normalization toward the 26.0% target and reducing free cash flow conversion.
Heightens liquidity pressure against $36.98B in current liabilities and increases refinancing costs at 6.28% pre-tax cost of debt, threatening capital allocation flexibility.
Current:2.7x leverage with $67.42B total debt against $1.14B cash
Contraction in non-US revenues heightens domestic geographic concentration and leaves cash generation disproportionately vulnerable to US Medicare drug price negotiations.
Current:40.75% ($25.50B combined international sales on $62.58B total revenue)
Alert ifInternational revenue share falling below 35.0% of total revenue
Pfizer's structural competitive strength relies heavily on its global commercial scale and distribution infrastructure. The firm generated $37.08B in the United States, $16.19B across international developed markets, and $9.31B in emerging markets in FY2025. In North America, distribution is funneled through long-term service agreements with three major wholesalers: McKesson (25%), Cencora (16%), and Cardinal Health (13%). While representing a 54% concentration, these partners function as logistical conduits to thousands of healthcare institutions rather than commercial decision-makers, giving Pfizer unmatched channel velocity.
To defend economic profits through the upcoming patent cliff transition, management is leveraging manufacturing scale to implement a $9.7B cumulative net cost reduction program through 2029. With $7.2B targeted for completion by the end of 2026, including $3.0B in manufacturing optimization, Pfizer is positioned to protect gross margins in the mid-70s range. This efficiency engine offsets top-line generic erosion until oncology assets such as Padcev and pipeline candidates in the $150B obesity TAM reach commercial scale.
Pfizer generates positive economic profits, with FY2025 ROIC of 11.92% exceeding its moderate cost of equity (Ke) of 7.33% and WACC of 6.67%. Baseline profitability is demonstrated by FY2025 operating income of $15.44B and free cash flow of $9.08B. However, sustaining this economic spread requires delivering $9.7B in cumulative net cost reductions through 2029 to offset projected top-line patent cliff contraction of -3.97% in FY2027.1,2,3,4,5
6.5/ 10
Narrow
Sources of advantage
01Intangible Assets (Patented Commercial Biopharmaceutical Portfolio) — Pfizer maintains an extensive commercial drug portfolio generating $51.66B in FY2025 product sales and $1.65B in royalty revenue. While patent portfolios protect specialty and oncology therapies, upcoming patent expirations on Eliquis and Vyndaqel introduce structural cash flow cliffs, moderating the durability of this advantage.Moderate
02Commercial Distribution and Global Scale Advantage — Pfizer possesses unmatched global distribution and logistical scale, generating $37.08B in US revenue, $16.19B in international developed markets, and $9.31B in emerging markets. Strategic wholesale distribution partnerships with McKesson (25%), Cencora (16%), and Cardinal Health (13%) create deep supply chain integration across hospital and retail pharmacy networks.Wide
03Manufacturing Scale and Operational Cost Efficiency — Pfizer leverages specialized manufacturing infrastructure to execute a multi-year cost optimization program delivering $9.7B in net savings through 2029, with $7.2B delivered by end-2026 and $3.0B in manufacturing optimization. This manufacturing scale supports guided gross margins in the mid-70s range, well above industry averages of 71.7%.Moderate
Patent Expirations (Loss of Exclusivity) on Core Blockbuster Therapies
high
18 to 36 months
Executing the $9.7B operational cost reduction program through 2029 and commercializing oncology pipeline assets acquired via Seagen, including Padcev expansion.4
U.S. Government Pricing Negotiations and Wholesaler Concentration
medium
12 to 24 months
Wholesalers function as logistics aggregators rather than end-payers, while geographic revenue diversification across international markets ($25.50B combined) cushions US statutory pricing changes.7
Elevated Balance Sheet Debt and Refinancing Burden
The Base scenario reflects the modal expected operating trajectory. Management delivers planned net cost savings across manufacturing and corporate functions, successfully stabilizing operating margins at normalized levels. However, patent expirations on core mature blockbusters cause moderate revenue contraction before pipeline launches take effect post-transition. Capital allocation remains dedicated to debt reduction and dividend maintenance. This path targets $25.83 with an estimated probability of 60.0%, representing a return of -9.9% from $28.67 to Fair value of $25.83. This path is confirmed by revenue tracking guided ranges and leverage declining steadily toward target levels.
Under the Bull scenario, Pfizer accelerates execution of its operational cost reduction program while commercial oncology launches exceed expectations. Operating margins expand beyond normalized levels as manufacturing efficiencies take hold. Label expansions in oncology and promising early data from metabolic combination trials catalyze multiple expansion toward peer averages. This path targets $28.85 with an estimated probability of 20.0%, offering an expected return of 0.6% compared to $28.67. Investors would confirm this path through consecutive quarters of margin outperformance and clinical label expansions by FY2027.
Meeting baseline forecasts confirms that operational cost savings are neutralizing patent expiration headwinds, keeping fundamental value centered at $25.83 relative to $28.67.
Miss
Downgrade the rating; Execute defensive risk management and accelerate capital preservation protocols across exposed accounts.
Trigger: Revenue falls below the guided range due to accelerated erosion across core mature franchises, or operating margins fail to expand due to restructuring friction.
An operational shortfall would prove that loss-of-exclusivity pressures are overwhelming cost mitigations, threatening dividend headroom and accelerating multiple de-rating.
Pfizer demonstrates stable underlying cash conversion, with cash from operations comfortably exceeding reported net income due to non-cash amortization of acquisition-related intangible assets. Wholesale receivables turnover remains disciplined through distribution agreements with national pharmaceutical logistics partners. While working capital movements reflect normal quarterly inventory rhythms, significant balance sheet debt and continuing restructuring disbursements absorb a substantial share of operating cash flow, limiting unencumbered discretionary capital.
Metrics to watch into the print
01
Metric:
Restructuring Net Cost Reduction Cadence
CurrentManagement has completed initial restructuring milestones and reaffirmed multi-year targets across manufacturing and organizational functions.
CurrentOperating margins are stabilizing following post-pandemic normalization, supported by gross margin targets in line with corporate expectations.
Why it matters
Margin trajectory reveals whether operational savings are converting into sustained operating profitability rather than being absorbed by commercial friction or inflation.
03
Metric:
Core Wholesaler Distribution Volume and Concentration
CurrentAgreements with major pharmaceutical distributors continue to operate smoothly under long-term commercial logistics arrangements.
Why it matters
Logistical stability across primary wholesale partners ensures seamless commercial channel delivery and protects cash flow collection velocity.
CurrentOperating cash flows are prioritized toward debt amortization to transition leverage downward over the multi-year planning horizon.
Why it matters
Lowering outstanding debt balances reduces interest expenses, improves credit metrics, and secures ongoing dividend distribution coverage.
05
Metric:
Clinical Milestones and Late-Stage Trial Data
CurrentOncology assets are progressing through label expansion trials while metabolic combination studies advance toward upcoming pivotal readouts.
Why it matters
Regulatory approvals and Phase Three trial successes determine whether new oncology and metabolic therapies can replace lost revenues after key exclusivity expiries.
Pfizer demonstrates substantial cash generation power, generating $11.70B in operating cash flow in FY2025. Capital expenditures were contained at $2.63B, yielding free cash flow of $9.08B. Cash conversion benefits from stable wholesale agreements with McKesson (25%), Cencora (16%), and Cardinal Health (13%). Normalized owner earnings stand at $12.39B based on 75% maintenance capex ($1.97B) and $6.59B depreciation, ensuring ongoing operations self-fund core commitments.5,6,7
Capital allocation is strictly circumscribed by debt obligations resulting from the Seagen acquisition. Total debt stands at $67.42B as of FY2025 ($63.48B as of September 2026), leaving balance sheet leverage around 2.7x with cash of $1.14B against current liabilities of $36.98B. Consequently, management has prioritized balance sheet deleveraging and maintaining the $1.72 annual dividend over share repurchases. Discretionary capital deployment is limited to approximately $6B in targeted business development.
The positive economic spread of ROIC (11.92%) over WACC (6.67%) validates Pfizer's capital efficiency, supported by gross margins in the mid-70s range. As the $9.7B cost reduction initiative takes effect, operating margins expand from 24.67% in FY2025 toward 26.0% by FY2030, defending return on invested capital as revenue stabilizes.
Operating Margin Normalization Driven by Structural Cost Elimination
Management is executing $9.7B in net cost reductions through 2029, with $7.2B delivered by end-2026, rebuilding operating income from $15.44B in FY2025.
Operating margin is projected to expand from 24.67% in FY2025 toward 24.8% in FY2026 and 26.0% by FY2030, insulating corporate profitability against generic revenue erosion.
Consensus estimates project revenue contraction of -0.55% in FY2026 to $62.24B and -3.97% in FY2027 to $59.77B on product sales of $51.66B.
Operating profit expansion relies entirely on cost reductions until post-2028, when new oncology and metabolic pipeline assets are expected to accelerate top-line recovery.
Robust Free Cash Flow Conversion Funds Deleveraging and Dividend Coverage
Free cash flow conversion of 77.5% from operating cash flow protects the $1.72 annual dividend while providing internal liquidity to amortize $67.42B in debt.
Pfizer Inc. (PFE) trades at 9.7x forward earnings against a peer median of 15.4x. Its EV/EBITDA of 8.5x compares with a peer median of 14.3x. The comparison uses 4 peers: Merck & Co. Inc., Gilead Sciences Inc., AbbVie Inc. and Sanofi, as of 2026-09-25 to 2026-09-26.
Bear cycle
The biopharmaceutical bear cycle is precipitated by severe patent cliffs on high-margin blockbuster products, leading to rapid 80-90% generic substitution and pricing erosion. Compounding this headwind, statutory pricing mandates such as Medicare negotiations compress realized gross margins in core developed markets. Concurrently, elevated financial debt from past mergers leaves leveraged biopharma operators vulnerable to higher refinancing costs, requiring defensive cost restructuring and restricting capital reinvestment.
Secular trends
Trend
Impact
Note
Global Population Aging and Chronic Disease Burden
positive
Demographic aging across major economies accelerates the prevalence of oncological and cardiovascular diseases, sustaining volume demand across Pfizer's commercial portfolio and international developed markets ($16.19B in FY2025 revenue).
Government Drug Pricing Scrutiny and Mandatory Price Negotiations
negative
Legislative drug price negotiations under Medicare in the United States ($37.08B in FY2025 revenue) restrict commercial pricing freedom on mature blockbusters, accelerating revenue erosion during loss-of-exclusivity transitions.
Adoption of Next-Generation Biologics and Antibody-Drug Conjugates (ADCs)
positive
Therapeutic shift toward biologics and antibody-drug conjugates (ADCs) provides longer commercial exclusivity and higher manufacturing barriers against generic erosion, positioning Pfizer's Seagen assets as long-term cash flow drivers.
Positioning
Pfizer occupies a transitional operating position within the global biopharmaceutical sector. While its $62.58B revenue base and $11.70B operating cash flow reflect dominant commercial scale, impending patent expirations drive projected top-line contraction (-3.97% in FY2027). With balance sheet leverage at 2.7x and total debt of $67.42B, Pfizer's positioning depends entirely on flawless execution of its $9.7B cost savings initiative to bridge the transition to post-2028 pipeline growth.1,3,4,6
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
-3.8%
Cost of capital 2 points higher
Trigger
Within 12 months
FV impact
-9.9%
Terminal multiple 20% lower
Trigger
Within 24 months
Alert ifNet debt to EBITDA rising above 3.5x during the transition period
